NSAIDs modulate clonal evolution in Barrett's esophagus.
Cancer is considered an outcome of decades-long clonal evolution fueled by acquisition of somatic genomic abnormalities (SGAs). Non-steroidal anti-inflammatory drugs (NSAIDs) have been shown to reduce cancer risk, including risk of progression from Barrett's esophagus (BE) to esophageal adenoca...
Main Authors: | Rumen L Kostadinov, Mary K Kuhner, Xiaohong Li, Carissa A Sanchez, Patricia C Galipeau, Thomas G Paulson, Cassandra L Sather, Amitabh Srivastava, Robert D Odze, Patricia L Blount, Thomas L Vaughan, Brian J Reid, Carlo C Maley |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2013-06-01
|
Series: | PLoS Genetics |
Online Access: | http://europepmc.org/articles/PMC3681672?pdf=render |
Similar Items
-
NSAID use and somatic exomic mutations in Barrett’s esophagus
by: Patricia C. Galipeau, et al.
Published: (2018-02-01) -
Correction to: NSAID use and somatic exomic mutations in Barrett’s esophagus
by: Patricia C. Galipeau, et al.
Published: (2019-03-01) -
p16 mutation spectrum in the premalignant condition Barrett's esophagus.
by: Thomas G Paulson, et al.
Published: (2008-01-01) -
The role of tobacco, alcohol, and obesity in neoplastic progression to esophageal adenocarcinoma: a prospective study of Barrett's esophagus.
by: Sheetal Hardikar, et al.
Published: (2013-01-01) -
NSAIDs modulate CDKN2A, TP53, and DNA content risk for progression to esophageal adenocarcinoma.
by: Patricia C Galipeau, et al.
Published: (2007-02-01)